文献速递造血干细胞移植与细胞治疗

接受造血干细胞移植患者住院姑息治疗干预的多中心随机试验

Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation.
PubMed 文献 · J Clin Oncol · 2025-06-23

在三个学术机构开展的多中心随机试验中,360例接受自体或异基因造血干细胞移植的成人被随机分配至住院姑息治疗干预组或常规护理组,干预组在移植住院期间每周与姑息治疗临床医生会面两次。结果显示,干预组在第2周的生活质量、抑郁和创伤后应激障碍症状均优于常规护理组,且创伤后应激障碍症状的改善在移植后6个月内持续存在。

要点

  • 住院期间每周两次姑息治疗会面可改善移植患者第2周的生活质量、抑郁和创伤后应激障碍症状。
  • 姑息治疗对创伤后应激障碍症状的改善在移植后6个月内持续存在。
  • 第2周患者自评焦虑在两组间无显著差异,其他患者报告结局在纵向分析中无差异。

核心结论

  • 姑息治疗使患者的生活质量、抑郁和创伤后应激障碍症状获得大幅改善,且对创伤后应激障碍症状的效应持续至移植后6个月。

研究设计与样本

  • 多中心随机试验,在三个学术机构纳入接受自体或异基因造血干细胞移植的成人,随机分配至住院姑息治疗干预组或常规护理组。
  • 干预组患者在移植住院期间每周与姑息治疗临床医生会面两次;常规护理组患者可按标准治疗转诊至姑息治疗。
  • 2018年10月至2022年7月期间入组了68.7%(360/524)的合格患者。

主要发现

  • 第2周时,干预组较常规护理组报告更好的生活质量(校正均数差[B]为6.3;SE为0.1;P < .001)。
  • 第2周时,干预组较常规护理组报告更低的抑郁(B为-1;SE为0.4;P = .026)。
  • 第2周时,干预组较常规护理组报告更少的创伤后应激障碍症状(B为-1.9;SE为0.9;P = .046)。
  • 第2周时,患者自评焦虑在两组间无显著差异。
  • 纵向分析中,干预组在移植后6个月内创伤后应激障碍症状下降更陡峭(斜率差为-0.9;SE为0.7;P = .012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients undergoing hematopoietic stem cell transplantation (HSCT) and their caregivers endure immense physical and psychological symptoms, which result in quality-of-life (QOL) impairments during HSCT. METHODS: We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) intervention or usual care. Intervention patients met with PC clinicians twice weekly during the HSCT hospitalization. Patients assigned to usual care could be referred to PC as per standard of care. We assessed QOL (patient: Functional Assessment of Cancer Therapy-Bone Marrow Transplant; caregiver: Caregiver-Oncology-QOL), depression and anxiety symptoms (Hospital-Anxiety-and-Depression-Scale), and patients' post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist) at baseline, week 2, and 3 and 6 months post-HSCT. The primary end point was patients' QOL at week 2 during hospitalization when patients experience their QOL nadir. We used linear regression, adjusting for baseline scores, to evaluate the effect of the intervention on patient-reported outcomes at week 2. We used linear mixed-effect models to assess the effect of the intervention on study outcomes longitudinally. RESULTS: We enrolled 68.7% (360/524) of eligible patients between October 2018 and July 2022. Compared with those receiving usual care, patients receiving the intervention reported better QOL (adjusted mean difference [B], 6.3; SE, 0.1; P < .001), lower depression (B, -1; SE, 0.4; P = .026), and fewer PTSD symptoms (B, -1.9; SE, 0.9; P = .046) at week 2. Patient-reported anxiety did not differ significantly between groups at week 2. In longitudinal analyses, patients receiving the intervention reported a steeper decline in PTSD symptoms over 6 months post-HSCT (slope difference, -0.9; SE, 0.7; P = .012). All other patient-reported outcomes did not differ longitudinally between the groups. CONCLUSION: PC led to substantial improvements in patients' QOL, depression, and PTSD symptoms with sustained effects on PTSD symptoms up to 6 months post-HSCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation. J Clin Oncol. 2025. PMID: 40549982. doi:10.1200/JCO-25-00378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。